SCHEMBL4884549

SCHEMBL4884549

FC(F)(F)Oc1ccc2ncnc(Nc3ccc(N4CCOCC4)cc3)c2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.68
MAPK1 P28482 2/20 0.68
AHR P35869 1/20 0.68
HTT P42858 1/20 0.68
ABL1 P00519 8/20 0.57
BCR P11274 8/20 0.57
PI4KB Q9UBF8 1/20 0.56
TTBK1 Q5TCY1 2/20 0.53
TTBK2 Q6IQ55 2/20 0.53
POLB P06746 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
GRM1 Q13255 1/20 0.50
TSHR P16473 2/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.48
EIF2AK2 P19525 1/20 0.48
NR4A1 P22736 1/20 0.47
PIM1 P11309 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4938197 0.85 MAPT (0.62) MAPTMAPK1AHRHTTABL1
SCHEMBL4008515 0.82 MAPT (0.80) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4886099 0.81 MAPT (0.78) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4888050 0.81 MAPT (1.00) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4007231 0.81 MAPT (0.78) MAPTMAPK1AHRHTTPI4KB
SCHEMBL14026144 0.80 MAPT (0.77) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4891594 0.80 MAPT (0.77) MAPTMAPK1AHRHTTPI4KB
SCHEMBL6920040 0.78 ABL1 (0.62) MAPTMAPK1ABL1BCRPOLB
SCHEMBL14026142 0.78 MAPK1 (0.72) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4007152 0.78 MAPK1 (0.72) MAPTMAPK1AHRHTTPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 MAPT 2064/4885MAPK1 1945/4885AHR 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.